Pharming Group (NASDAQ:PHAR) Announces Earnings Results

Pharming Group (NASDAQ:PHAR) released its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12), FiscalAI reports. Pharming Group had a return on equity of 1.08% and a net margin of 0.71%.The firm had revenue of $72.45 million for the quarter, compared to analyst estimates of $92.06 million.

Here are the key takeaways from Pharming Group’s conference call:

• RUCONEST revenue fell 15% YoY in Q1, driven mainly by an anticipated specialty‑pharmacy inventory drawdown (~8%) and the planned exit from ex‑U.S. markets (~3%); management says patient retention and new enrollments/prescribers are strong but expects near‑term pressure in Q2 before normalization in H2.
• Joenja grew 34% YoY to $14.1M with U.S. patients up 25% (127 on paid therapy); management expects launches in Germany and Japan this year and has resubmitted a pediatric sNDA for the higher doses with an FDA decision expected in ~6 months and a second sNDA planned for summer.
• The pipeline has multiple near‑term catalysts — two phase II readouts for leniolisib in broader PIDs/CVID expected later this year (encouraging expanded‑access data in six severe CVID patients were presented) and completion of enrollment for the registrational study of napazimone this year with a readout next year, each described as potential billion‑dollar opportunities.
• Management reiterated 2026 revenue guidance of $405–425M (8–13% growth), delivered positive Q1 operating cash flow (€2M) and €171.8M in cash/securities, and highlighted continued cost discipline (including a 20% G&A structural reduction) while funding incremental R&D — though cash declined partly due to a €12.3M lease termination payment.

Pharming Group Price Performance

PHAR stock traded down $4.40 during midday trading on Thursday, reaching $12.00. The company had a trading volume of 96,064 shares, compared to its average volume of 24,435. The company has a market capitalization of $847.50 million, a price-to-earnings ratio of 1,200.00 and a beta of 0.04. The stock has a 50 day moving average price of $16.37 and a 200-day moving average price of $16.58. Pharming Group has a 1-year low of $8.69 and a 1-year high of $21.34. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.59 and a quick ratio of 2.03.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PHAR shares. Oppenheimer reissued an “outperform” rating and issued a $41.00 price objective (down from $42.00) on shares of Pharming Group in a report on Friday, March 13th. Canaccord Genuity Group started coverage on Pharming Group in a report on Friday, April 10th. They issued a “buy” rating and a $37.00 price objective for the company. Zacks Research raised Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Weiss Ratings raised Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, April 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Tuesday, March 24th. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Pharming Group has a consensus rating of “Moderate Buy” and an average target price of $38.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. NewEdge Advisors LLC grew its holdings in shares of Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Pharming Group in the fourth quarter worth approximately $360,000. SmartHarvest Portfolios LLC bought a new position in shares of Pharming Group during the 4th quarter worth approximately $224,000. Finally, EverSource Wealth Advisors LLC bought a new position in shares of Pharming Group during the 2nd quarter worth approximately $32,000. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.